| INTRODUC TI ON
Lysinuric protein intolerance (LPI) is a rare autosomal recessive transport disorder of the cationic amino acids lysine, arginine and ornithine, affecting intestine, lungs, liver and renal tubules. and deficient B-cell function have also been reported. [5] [6] [7] Renal insufficiency is a common complication associated with LPI that may progress to end-stage renal disease requiring renal transplantation. Severe pulmonary complications, including pulmonary fibrosis and alveolar proteinosis, may also occur. [8] [9] [10] [11] Several LPI patients with hemophagocytic lymphohistiocytosis syndrome (HLH) have been reported in the literature. Serum ferritin is constantly markedly elevated in LPI patients, further referring to ongoing hemophagocytosis. 12 Lysinuric protein intolerance is more prevalent in Finland (1 in 60 000) than elsewhere in the world due to Finnish disease heritage, but several patients have been reported from, for example, Italy, Tunisia, and Japan. 13, 14 LPI is caused by bi-allelic mutations in the gene SLC7A7, which encodes the y + LAT1 protein, the catalytic light chain subunit of the heteromeric amino acid transporter. [15] [16] [17] [18] All the Finnish patients share the same mutation, a substitution of T for A at cDNA position 1181-2A →T (LPI Fin ). 2 It has been recognized that LPI patients may display bleeding events. Even fatal haemorrhage has been observed postpartum and otherwise, but the mechanisms rendering the LPI patients prone to bleeding are unknown, although low platelet counts, low fibrinogen, high D-dimer and elevated levels of thrombin-antithrombin complex (TAT) have been observed. 19, 20 The prevalence and pathogenesis of coagulopathy associated with LPI has not been systemically evaluated, and case reports on this subject are sparse. The aim of this study was to characterize alterations in haemostatic and fibrinolytic markers in LPI patients compared with controls and the renal impairment. The motivation for this study is the unmet need to guide the perioperative management of these patients in general, specifically during renal transplantation.
| ME THODS

| Subjects
The diagnostics and annual follow-up of Finnish LPI patients is centralized to the Department of Pediatrics at the Turku University Hospital. The current study cohort consisted of 15 adult LPI patients (8 women) available for analysis. The median age of the participants was 45 years (ranging 23-60 years). Our study was approved by the ethics committee of Turku University Hospital, and informed consent was obtained in accordance with the Declaration of Helsinki.
Eleven of the patients used lysine supplementation. One patient had regular dipyridamole/acetylsalicylic acid medication due to a history of a transient ischaemic attack. One patient had previously undergone a splenectomy, and another had both a kidney transplant and splenectomy. At the time of the study, one patient had developed end-stage renal disease and needed regular erythropoietin injections to treat renal anaemia. Control plasma was collected from nonmatched volunteer donors in the same age range as our LPI patients.
All volunteers had normal body mass index, no known illnesses, medications nor any history of bleeds.
| Sample collection
Blood samples were collected in citrate anticoagulant (109 mmol/L sodium citrate) from the patients and healthy volunteers. Platelet-poor activity, but together with lowered fibrinogen and FXIII. Thrombin generation (TG) was reduced in vitro, according to CAT-derived endogenous thrombin potential, but in vivo TG was enhanced in the form of circulating prothrombin fragment 1 and 2
values. Very high D-dimer and plasmin-α2-antiplasmin (PAP) complex levels coincided with shortened CLT in vitro.
Conclusions:
Defective primary haemostasis, coagulopathy, fibrin abnormality (FIBTEM, CT and CLT), low TG in vitro and clearly augmented fibrinolysis (PAP and D-dimer) in vivo were all detected in LPI. Altered fibrin generation and hyperfibrinolysis were associated with the metabolic and renal defect, suggesting a pathogenetic link in LPI.
K E Y W O R D S
coagulation disorder, fibrinolysis, lysinuric protein intolerance, thrombin generation plasma (PPP) was processed by centrifugation at 2500 g for 15 minutes
at room temperature. PPP was stored in aliquots at −80°C.
| LPI routine follow-up
All LPI patients were clinically examined (weight, blood pressure), including routine follow-up metabolic assays: total blood cell count, plasma ferritin, plasma alanine aminotransferase (ALT), plasma creatinine (P-Crea), urinary creatinine (U-Crea), serum cystatin C, urine beta2-microglobulin for an early marker of renal insufficiency, plasma and urinary amino acids, including plasma lysine (P-LYS) and urinary lysine (U-LYS), plasma ammonia (P-NH 4 ), total plasma cholesterol, low-density lipoprotein (LDL), high-density lipoprotein (HDL), triglycerides, plasma prealbumin, and capillary blood gas analysis. To estimate the glomerular filtration rate (eGFR), the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation was used. 21 Urinary lysine levels without creatinine correction were calculated by multiplying U-LYS with U-Crea.
| Clinical evaluation of bleeding tendency
The ISTH/SSC-BAT questionnaire 22 for scoring the severity of the bleeding tendency was used to evaluate the clinical impact of LPI on haemostasis. Normal values of this bleeding score (BS) for men are <4 points and <6 points for women. 
| ROTEM
| Fibrin generation and clot lysis test
| Statistics
The median and the range were calculated and reported for all measurements. The Shapiro-Wilk normality test was performed. Groups were compared using the Mann-Whitney test. Correlations were calculated with the Spearman correlation coefficient, also using linear regression models where pertinent. IBM SPSS Statistics 22 was used to calculate statistics, and P-values <.05 were considered statistically significant.
| RE SULTS
| Bleeding score
Nine patients presented with normal BS. Six patients had elevated BS (Table 1) , and three of them were women. Median BS for women was 5 (range 0-9), and for men 2 (range −1-6) points. Two of the three women had experienced severe postpartum haemorrhage. Besides labour, one of these two women also bled during a splenectomy due to abdominal trauma and kidney transplant surgery. The third woman had menorrhagia combined with mucocutaneous bleeds.
One man bled after a splenectomy due to spontaneous cyst rupture, the other had gastrointestinal (GI) haemorrhage and the third had multiple mucocutaneous bleeds related to dental procedures. In general, most common bleeding manifestations occurred from minor wounds, oral cavity, after tooth/teeth extraction, after surgery or major trauma, menorrhagia and postpartum haemorrhage. Two women had normal labour and puerperium, and one man underwent minor surgery without bleeding complications. Other seven patients
were not subjected to surgical procedures. No muscle hematomas, haemarthrosis nor other spontaneous bleeds, except for the one GI bleed, were reported. Ten patients had both mild anaemia and iron substitution (Table 1) .
| Routine clinical chemistry analyses
The plasma levels of ALT were moderately elevated in three patients, as was NH 4 (up to 62 μmol/L) in four patients, but prealbumin was normal in all, excluding major liver impairment in our patients. Eleven patients had elevated plasma creatinine concentration, and 12 patients had reduced eGFR. Urinary creatinine (U-crea) measured from 12 patients was normal. Serum cystatin C was also elevated in 10 patients. Only one patient had normal urine beta2-microglobulin, while it was elevated in all others. P-LYS was reduced in four patients, and U-LYS was high in all 12 with the measurement available. Capillary blood gas analysis in 13 patients showed normal pH in 7, whereas only three presented with normal base excess, and five patients had a normal bicarbonate level (Table 2) .
Hyperlipidaemia was common, especially hypertriglyceridae- triglycerides. Ten patients had cholesterol medication (simvastatin), but only one patient had normal cholesterol values without medication. Four patients reached normal LDL levels with their medication, whereas six remained hypercholesterolemic (Table 2 ).
| Blood cell counts, PFA-100, coagulation activity and D-dimer
Median haemoglobin in women was 123 g/L (range 109-137 g/L) and 131 g/L in men (ranging 106-147 g/L). Six presented with mild thrombocytopenia. White blood cell count was normal, whereas plasma ferritin levels were high in all patients (Table 3 ). Although none of the patients had the diagnosis of HLH, 11/15 patients met 3 of its 8 diagnostic criteria, 26 of which 5 would indicate HLH. These observations included splenomegaly, hypertriglycerideamia or hypofibrinogenemia and ferritin levels exceeding 500 μg/L. PT, APTT, and TT and VWF:Ac were all normal (Table 3) . However, despite the normal VWF:Ac, only four patients had normal PFA closure time in the epinephrine cartridge, being prolonged among the others (Table 3) (Table S1 on the individual platelet counts and PFA-100 results).
Functional fibrinogen level was low, although in the normal range, but four patients exhibited fibrinogen below 1.7 g/L without prolonged thrombin time (Table 3 ). Median FXIII:C was also low, and only four patients had FXIII:C activity within the reference range TA B L E 2 Routine metabolic and renal follow-up (Table 3) . However, the most striking and uniform finding was the elevated D-dimer level in all patients (Table 3 , individual fibrinogen, FXIII and D-dimer in Table S1 ).
| In vitro and in vivo thrombin generation
In vitro thrombin generation (TG), as determined by the TF-triggered CAT, was partially impaired compared with healthy controls. Lag time ( Figure 1A ) and peak TG ( Figure 1B ) did not differ from healthy controls. However, ETP was significantly reduced in LPI (P = .02) ( Figure 1C ). In contrast, circulating biomarker F1 + 2 implied strong in vivo TG (Table 3) , as it exceeded 1200 (range 961 ->1200) pmol/L. In healthy individuals, the F1 + 2 median was 178 (range 91-272) pmol/L.
| In vitro fibrin clot formation
In ROTEM, some variables differed from normal in LPI patients. As expected, FIBTEM MCF recognized fibrinogen levels below the ref-
erence range (Table 3 ). In addition, seven patients had decreased FIBTEM MCF, beyond the four with fibrinogen level <1.7 g/L (Table 3) . Besides low fibrinogen, low FXIII:C levels may contribute to FIBTEM MCF, and indeed, FXIII:C showed correlation with FIBTEM MCF (r = .63, P = .01). INTEM CT was normal, but six patients showed prolonged CFT, and four displayed declined MCF.
EXTEM CT and CFT were prolonged in seven patients, and MCF was reduced in five. All EXTEM variables and INTEM CFT, A10 and MCF correlated significantly with fibrinogen levels, but not with platelet counts. Both INTEM and EXTEM ML were within reference ranges (Table 4) . Fibrin clot formation triggered with low TF and was traced by ODmax measurement, revealing a median CT that was significantly prolonged in LPI compared to controls (P < .001) ( Figure 1E ).
The median ODmax was decreased in LPI (P = .03) ( Figure 1D ).
| Fibrinolysis
As a sign of enhanced in vivo fibrinolysis, together with D-dimer, circulating PAP levels were also extremely high, exceeding 2000 μg/L and the calibration curve range. In healthy individuals, the median PAP was 638 μg/L (range 430-862 μg/L). In comparison with healthy controls, median plasminogen was elevated (P = .01) (Figure 2A ), while α2-antiplasmin levels were lower (P < .001) ( Figure 2B ). This resulted in clearly higher plasminogen/α2-antiplasmin ratio (median 1.50; range 1.10-2.02) than in healthy controls (0.96; range 0.82-1.16) (P < .001) indicating increased fibrinolytic capacity in LPI. TAFI levels were slightly reduced in 5 patients (Table 3) . Again, compatible with enhanced fibrinolysis in general, LPI patients showed shorter CLT (P < .01) ( Figure 2C ) than healthy controls.
| Clinical, coagulation and fibrinolysis biomarker correlations and renal impairment
Renal function markers eGFR and Cystatin C correlated with urinary lysine levels (r = .63, P = .03 and r = −.64, P = .03, respectively).
Intriguingly, renal function also correlated with both fibrin formation and fibrinolytic capacity (Table 5) . Accordingly, creatinine, eGFR, cystatin C, base excess and bicarbonate levels all correlated with impaired fibrin formation (ODmax), decreased α2-antiplasmin and elevated D-dimer (Table 5 ) . In addition, creatinine correlated negatively with fibrinogen and FIBTEM MCF (r = −.56, P = .03 and r = −.57, P = .03, respectively), unlike other renal markers.
| D ISCUSS I ON
In clinical management, the bleeding disorder associated with LPI should alert to act appropriately, as upon LPI progression, Mucocutaneous bleeds mainly triggered with invasive and surgical interventions or postpartum are typical. We encountered impaired primary haemostasis and strongly elevated thrombin formation and fibrinolysis activation in vivo, while subsequently the in vitro coagulation responses were attenuated. Based on previous studies and now confirmed by ours, renal insufficiency in LPI associates with lysine loss in urine. 27 According to our study, markers of abnormal fibrin and enhanced fibrinolysis associated with metabolic abnormalities and renal insufficiency.
TA B L E 3 Haematologic and fibrinolytic variables
Our study carries some limitations. We did not include a matched control group with renal insufficiency to the study design. The complex pathogenesis of renal diseases carries several variants with highly specific alterations in the coagulation and fibrinolytic system, rendering the choice of the potential control group difficult. We herein suggest an alternative mechanism for the high F1 + 2, PAP, and D-dimer and propose that this may partially reflect impaired hepatic clearance. Although y + LAT-1 is not expressed in liver, hepatic enlargement with relevant histopathological changes is found in the majority of LPI patients. 4 Indicators of in vivo coagulation (F1 + 2) and fibrinolysis (D-dimer and PAP) are breakdown products or protease-inhibitor complexes with relatively short half-lives.
The hepatic clearance of these molecule complexes may be delayed in LPI due to liver involvement, as seen in cirrhosis. 39 The abovementioned metabolic complexes are highly elevated in LPI, albeit clinical liver disease is not present. In addition, lipid metabolism of combined hyperlipidaemia 40 further overloads liver in LPI. Further studies are required to ascertain whether impaired hepatic clearance contributes to elevated levels of in vivo indicators of coagulation and fibrinolysis in LPI.
Our LPI patients presented with moderate renal insufficiency, confirmed by elevated creatinine, cystatin C and urine beta2-microglobulin levels. At normal pH, base excess and bicarbonate levels accorded with systemic acidosis due to chronic renal insufficiency and tubular dysfunction via LPI. 41 Pathophysiological mechanisms of renal impairment in LPI are not fully elucidated, but several explanations have been suggested. Lysine trapped inside the proximal tubular cells causes direct toxicity and apoptosis. 27, 42 Furthermore, oral lysine supplementation in rats promotes proteinuria and inhibits albumin reabsorption by the proximal tubular cells. 42 According to the second hypothesis, arginine accumulation in renal cells may promote local synthesis of nitric oxide and trigger inflammation and immune system overstimulation, causing immune glomerulopathy. 41, 43, 44 The severity of renal insufficiency in LPI correlated with the overt fibrinolysis, as α2-antiplasmin and D-dimer clearly associated with the loss of renal function. During hyperfibrinolysis, altered plasminogen/α2-antiplasmin ratio may lead to plasminemia, which is harmful to kidneys. 45 Also, ODmax, a variable derived from fibrin generation tracings, and affected in particular by both the fibrinogen level and the amount of thrombin generated, revealed a significant association with the markers of renal function. All authors had full access to all data in the study and take responsibility for the integrity of data and the accuracy of the data analysis.
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